Unitaid is pleased to share its 2017 results report (French), which shows significant progress across Unitaid’s portfolio in supporting our three strategic objectives: fostering innovation, increasing access to better health products, and working with partners to scale up our innovations.
To meet our goals, we need a clear way of measuring our progress toward them. The results report shows Unitaid’s performance in a number of critical areas and compares it to the goals we’ve set for ourselves, including Unitaid’s Strategic and Operational Key Performance Indicators.
All Unitaid grants that closed during 2017 fall within the scope of the report. Highlights include the STEP-TB program, which secured the availability of the first appropriately dosed, good-tasting tuberculosis medicine for children, brought it to market at an affordable price, and has led, with the support of scale-up partners, to the medicine’s adoption in 79 countries.
The report also showcases projects that are under way and already demonstrating potential for impact in areas such as self-testing for HIV, development of new insecticides to kill resistant mosquitoes that spread malaria, and creating access to affordable, generic versions of the world’s best HIV drugs in lower-income countries.
View All News